Novo to buy mid-stage heart failure biotech Cardior for up to $1.1B
25 Mar 2024
AcquisitionPhase 2
Novo Nordisk plans to acquire German biotech Cardior Pharmaceuticals, a Phase 2 RNA startup, for up to $1.1 billion to boost its presence in cardiovascular disease, the Danish drug giant said Monday morning.
The move comes three weeks after Novo’s obesity drug Wegovy received a label expansion to include the reduction of cardiovascular events, an approval that could open the doors to more coverage. Last year, Novo’s acquisitions were focused on obesity, with a $1.075 billion deal for Inversago and Embark Biotech for about $500 million total.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.